The integrator operating model
Bridging the translation gap between scientific innovation and commercial reality.
Most MedTech innovations fail at the point of commercial translation, not in the laboratory or the clinic.
~ 65% of new MedTech launches miss their first-year revenue targets. In midsize companies, this rarely stems from flawed engineering or weak clinical trials. It happens because the trial was designed to satisfy a regulator, while the buyer requires a completely different economic currency to fund it.
Yet, when organisations attempt to fix this, they usually search for a "unicorn", a single leader expected to master EU MDR technical files, local hospital DRGs, outpatient economics, and commercial sales execution.
Expecting one person to carry this cognitive load creates a fragile bottleneck.
Translation is not an individual hire. It has to be an organisational capability.
Today, we are publishing our latest white paper: "The Integrator Operating Model: Bridging the Translation Gap Between Scientific Innovation and Commercial Reality in MedTech."
Inside, we break down:
The 4 parameters that dictate your structural choices
market heterogeneity,
portfolio complexity and novelty,
evidence burden and reimbursement volatility,
resource bandwidth and scale
The 3 operating archetypes
Value Stream Pods,
Translation CoEs, and
Value Office Matrices
Practical roadmaps to rewire decision rights and shared metrics.
Buoyancy Health Strategy
Steady. Strategic. Scalable Healthcare Growth
© 2025 Buoyancy Health Strategy Ltd. All rights reserved.